Literature DB >> 23952339

Dimorphic HLA-B signal peptides differentially influence HLA-E- and natural killer cell-mediated cytolysis of HIV-1-infected target cells.

A M Merino1, S Sabbaj, J Easlick, P Goepfert, R A Kaslow, J Tang.   

Abstract

As a mechanism of self-protection, signal peptides cleaved from human leukocyte antigen (HLA) class I products bind to HLA-E before the complex interacts with the natural killer (NK) cell receptor CD94/NKG2A to inhibit NK-mediated cell lysis. Two types of the signal peptides differ in their position 2 (P2) anchor residue, with P2-methionine (P2-M) having higher HLA-E binding affinity than P2-threonine (P2-T). All HLA-A and HLA-C molecules carry P2-M, whereas HLA-B products have either P2-M or P2-T. Epidemiological evidence suggests that P2-M is unfavourable in the context of HIV-1 infection, being associated with accelerated acquisition of HIV-1 infection in two African cohorts. To begin elucidating the functional mechanism, we studied NK-mediated killing of CD4(+) T cells and monocyte-derived macrophages infected with two laboratory-adapted HIV-1 strains and two transmitted/founder (T/F) viruses. In the presence of target cells derived from individuals with the three HLA-B P2 genotypes (M/M, M/T and T/T), NK-mediated cytolysis was elevated consistently for P2-T in a dose-dependent manner for all cell and virus combinations tested (P = 0·008-0·03). Treatment of target cells with an anti-HLA-E monoclonal antibody restored NK-mediated cytolysis of cells expressing P2-M. Observations on cell lysis were also substantiated by measurements of HIV-1 p24 antigen in the culture supernatants. Overall, our experiments indicate that the anti-HIV-1 function mediated by NK cells is compromised by P2-M, corroborating the association of HLA-B genotype encoding P2-M with accelerated HIV-1 acquisition.
© 2013 British Society for Immunology.

Entities:  

Keywords:  HIV-1; HLA-B; HLA-E; natural killer cell; signal peptide

Mesh:

Substances:

Year:  2013        PMID: 23952339      PMCID: PMC3826307          DOI: 10.1111/cei.12187

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Intramembrane proteolysis of signal peptides: an essential step in the generation of HLA-E epitopes.

Authors:  M K Lemberg; F A Bland; A Weihofen; V M Braud; B Martoglio
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

2.  HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities.

Authors:  Roland K Strong; Margaret A Holmes; Pingwei Li; Laura Braun; Ni Lee; Daniel E Geraghty
Journal:  J Biol Chem       Date:  2002-10-30       Impact factor: 5.157

3.  Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E.

Authors:  Felicity A Bland; Marius K Lemberg; Andrew J McMichael; Bruno Martoglio; Veronique M Braud
Journal:  J Biol Chem       Date:  2003-06-23       Impact factor: 5.157

4.  Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2.

Authors:  Joseph D Miller; Dominique A Weber; Chris Ibegbu; Jan Pohl; John D Altman; Peter E Jensen
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

Review 5.  The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy.

Authors:  Jianming Tang; Richard A Kaslow
Journal:  AIDS       Date:  2003       Impact factor: 4.177

6.  Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis.

Authors:  M Ulbrecht; S Martinozzi; M Grzeschik; H Hengel; J W Ellwart; M Pla; E H Weiss
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

7.  Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.

Authors:  Christina Ochsenbauer; Tara G Edmonds; Haitao Ding; Brandon F Keele; Julie Decker; Maria G Salazar; Jesus F Salazar-Gonzalez; Robin Shattock; Barton F Haynes; George M Shaw; Beatrice H Hahn; John C Kappes
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

8.  Mechanisms for genetically predetermined differential quantitative expression of HLA-A and -B antigens.

Authors:  K Liu; K J Kao
Journal:  Hum Immunol       Date:  2000-08       Impact factor: 2.850

9.  Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat.

Authors:  M Zhang; X Li; X Pang; L Ding; O Wood; K Clouse; I Hewlett; A I Dayton
Journal:  J Biomed Sci       Date:  2001 May-Jun       Impact factor: 8.410

10.  Peptide binding characteristics of the non-classical class Ib MHC molecule HLA-E assessed by a recombinant random peptide approach.

Authors:  J Stevens; E Joly; J Trowsdale; G W Butcher
Journal:  BMC Immunol       Date:  2001-06-20       Impact factor: 3.615

View more
  20 in total

1.  Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity.

Authors:  Michael J Ombrello; Yohei Kirino; Paul I W de Bakker; Ahmet Gül; Daniel L Kastner; Elaine F Remmers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

2.  Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates.

Authors:  Heather A Prentice; Matthew A Price; Travis R Porter; Emmanuel Cormier; Michael J Mugavero; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang
Journal:  Virology       Date:  2013-12-12       Impact factor: 3.616

3.  Impact of HLA Allele-KIR Pairs on HIV Clinical Outcome in South Africa.

Authors:  Masahiko Mori; Ellen Leitman; Bruce Walker; Thumbi Ndung'u; Mary Carrington; Philip Goulder
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

4.  Class I HLA haplotypes form two schools that educate NK cells in different ways.

Authors:  Amir Horowitz; Zakia Djaoud; Neda Nemat-Gorgani; Jeroen Blokhuis; Hugo G Hilton; Vivien Béziat; Karl-Johan Malmberg; Paul J Norman; Lisbeth A Guethlein; Peter Parham
Journal:  Sci Immunol       Date:  2016-09-09

5.  The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Authors:  Alexander Hallner; Elin Bernson; Brwa Ali Hussein; Frida Ewald Sander; Mats Brune; Johan Aurelius; Anna Martner; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Blood       Date:  2019-01-15       Impact factor: 22.113

Review 6.  The immunogenetics of Behçet's disease: A comprehensive review.

Authors:  Masaki Takeuchi; Daniel L Kastner; Elaine F Remmers
Journal:  J Autoimmun       Date:  2015-09-05       Impact factor: 7.094

Review 7.  Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.

Authors:  Sarah Cooley; Peter Parham; Jeffrey S Miller
Journal:  Blood       Date:  2018-01-22       Impact factor: 25.476

8.  Immunogenetic influences on acquisition of HIV-1 infection: consensus findings from two African cohorts point to an enhancer element in IL19 (1q32.2).

Authors:  X Li; K Zhang; N M Pajewski; I Brill; H A Prentice; S Shrestha; W Kilembe; E Karita; S Allen; E Hunter; R A Kaslow; J Tang
Journal:  Genes Immun       Date:  2015-01-29       Impact factor: 2.676

Review 9.  HLA-E: a novel player for histocompatibility.

Authors:  Thomas Kraemer; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-10-20       Impact factor: 4.818

Review 10.  Immunogenetic determinants of heterosexual HIV-1 transmission: key findings and lessons from two distinct African cohorts.

Authors:  Jianming Tang
Journal:  Genes Immun       Date:  2021-05-01       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.